# Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring

Study · id `cardio:ct-nct06873828` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06873828](<https://clinicaltrials.gov/study/NCT06873828>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06873828

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06873828. Non-randomized; no masking; primary purpose diagnostic. Start 2025-03 (anticipated); primary completion 2025-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06873828, source copy `cardio:ctgov-nct06873828-2025-03-13`, retrieved 2026-10-31)
- Planned start: 2025-03 (anticipated) (ClinicalTrials.gov record NCT06873828, source copy `cardio:ctgov-nct06873828-2025-03-13`, retrieved 2026-10-31)
- Primary completion: 2025-10 (anticipated) (ClinicalTrials.gov record NCT06873828, source copy `cardio:ctgov-nct06873828-2025-03-13`, retrieved 2026-10-31)
- Completion: 2025-10 (anticipated) (ClinicalTrials.gov record NCT06873828, source copy `cardio:ctgov-nct06873828-2025-03-13`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06873828-2025-03-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
- Acronym: ATP-HCM
- Condition: Hypertrophic Cardiomyopathy
- Intervention (Device): ATP-C135
- Intervention (Device): ATP-C75
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: 625dd39bd9a5c470b84962ab004ff5783e06de15300efd075aef1b91dc59a46f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
